Cargando…

SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase

Retinoblastoma protein (Rb) is a prototypical tumor suppressor that is vital to the negative regulation of the cell cycle and tumor progression. Hypo-phosphorylated Rb is associated with G0/G1 arrest by suppressing E2F transcription factor activity, whereas Rb hyper-phosphorylation allows E2F releas...

Descripción completa

Detalles Bibliográficos
Autores principales: Meng, Fengxi, Qian, Jiang, Yue, Han, Li, Xiaofeng, Xue, Kang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957593/
https://www.ncbi.nlm.nih.gov/pubmed/27163259
http://dx.doi.org/10.1080/15384101.2016.1182267
_version_ 1782444196593926144
author Meng, Fengxi
Qian, Jiang
Yue, Han
Li, Xiaofeng
Xue, Kang
author_facet Meng, Fengxi
Qian, Jiang
Yue, Han
Li, Xiaofeng
Xue, Kang
author_sort Meng, Fengxi
collection PubMed
description Retinoblastoma protein (Rb) is a prototypical tumor suppressor that is vital to the negative regulation of the cell cycle and tumor progression. Hypo-phosphorylated Rb is associated with G0/G1 arrest by suppressing E2F transcription factor activity, whereas Rb hyper-phosphorylation allows E2F release and cell cycle progression from G0/G1 to S phase. However, the factors that regulate cyclin-dependent protein kinase (CDK)-dependent hyper-phosphorylation of Rb during the cell cycle remain obscure. In this study, we show that throughout the cell cycle, Rb is specifically small ubiquitin-like modifier (SUMO)ylated at early G1 phase. SUMOylation of Rb stimulates its phosphorylation level by recruiting a SUMO-interaction motif (SIM)-containing kinase CDK2, leading to Rb hyper-phosphorylation and E2F-1 release. In contrast, a SUMO-deficient Rb mutant results in reduced SUMOylation and phosphorylation, weakened CDK2 binding, and attenuated E2F-1 sequestration. Furthermore, we reveal that Rb SUMOylation is required for cell proliferation. Therefore, our study describes a novel mechanism that regulates Rb phosphorylation during cell cycle progression.
format Online
Article
Text
id pubmed-4957593
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-49575932016-08-05 SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase Meng, Fengxi Qian, Jiang Yue, Han Li, Xiaofeng Xue, Kang Cell Cycle Reports Retinoblastoma protein (Rb) is a prototypical tumor suppressor that is vital to the negative regulation of the cell cycle and tumor progression. Hypo-phosphorylated Rb is associated with G0/G1 arrest by suppressing E2F transcription factor activity, whereas Rb hyper-phosphorylation allows E2F release and cell cycle progression from G0/G1 to S phase. However, the factors that regulate cyclin-dependent protein kinase (CDK)-dependent hyper-phosphorylation of Rb during the cell cycle remain obscure. In this study, we show that throughout the cell cycle, Rb is specifically small ubiquitin-like modifier (SUMO)ylated at early G1 phase. SUMOylation of Rb stimulates its phosphorylation level by recruiting a SUMO-interaction motif (SIM)-containing kinase CDK2, leading to Rb hyper-phosphorylation and E2F-1 release. In contrast, a SUMO-deficient Rb mutant results in reduced SUMOylation and phosphorylation, weakened CDK2 binding, and attenuated E2F-1 sequestration. Furthermore, we reveal that Rb SUMOylation is required for cell proliferation. Therefore, our study describes a novel mechanism that regulates Rb phosphorylation during cell cycle progression. Taylor & Francis 2016-05-10 /pmc/articles/PMC4957593/ /pubmed/27163259 http://dx.doi.org/10.1080/15384101.2016.1182267 Text en © 2016 The Author(s). Published with license by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.
spellingShingle Reports
Meng, Fengxi
Qian, Jiang
Yue, Han
Li, Xiaofeng
Xue, Kang
SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase
title SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase
title_full SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase
title_fullStr SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase
title_full_unstemmed SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase
title_short SUMOylation of Rb enhances its binding with CDK2 and phosphorylation at early G1 phase
title_sort sumoylation of rb enhances its binding with cdk2 and phosphorylation at early g1 phase
topic Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4957593/
https://www.ncbi.nlm.nih.gov/pubmed/27163259
http://dx.doi.org/10.1080/15384101.2016.1182267
work_keys_str_mv AT mengfengxi sumoylationofrbenhancesitsbindingwithcdk2andphosphorylationatearlyg1phase
AT qianjiang sumoylationofrbenhancesitsbindingwithcdk2andphosphorylationatearlyg1phase
AT yuehan sumoylationofrbenhancesitsbindingwithcdk2andphosphorylationatearlyg1phase
AT lixiaofeng sumoylationofrbenhancesitsbindingwithcdk2andphosphorylationatearlyg1phase
AT xuekang sumoylationofrbenhancesitsbindingwithcdk2andphosphorylationatearlyg1phase